CDXS News and Press, Codexis Inc. From 02/25/19

REDWOOD CITY, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Laurie Heilmann to Senior Vice President of Business Development and Marketing. Heilmann brings to Codexis more than 30 years of leadersh...

REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial results after market close on Tuesday, February 26, 2019. Codexis management will hold an in...

Nestlé Health Science has exercised its option for exclusive rights to develop and commercialize Codexis' ( CDXS +1.4% ) CDX-6114 for the management of phenylketonuria (PKU). Nestlé will now take over all future development and commercialization activities and costs. More new...

REDWOOD CITY, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ ...

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...

REDWOOD CITY, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova ®...

Amyris (NASDAQ: AMRS ) +41%  on $255M cannabinoid deal . More news on: Amyris, Inc., Melinta Therapeutics, Moleculin Biotech, Inc., Stocks on the move, Read more ...

Codexis (NASDAQ: CDXS ) is up  13%  premarket on light volume in reaction to its multiyear agreement with Merck (NYSE: MRK ) under which CDXS will install its CodeEvolver protein engineering technology upgrades into MRK's platform license installation and will maintain the upgrad...

REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install certain CodeEvolver ® protein ...